Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.47 |
| ▸ | MGLL | Q99685 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13157956 | 1.00 | TSHR (0.49) | TSHRRECQLSLC18A3MGLLLMNA | |
| SCHEMBL13158009 | 0.86 | FASN (0.46) | TSHRSLC18A3MGLLLMNASLC6A7 | |
| SCHEMBL3092760 | 0.86 | FASN (0.46) | TSHRSLC18A3MGLLLMNASLC6A7 | |
| SCHEMBL3105142 | 0.85 | POLB (0.55) | SLC18A3MGLLLMNAPOLBMEN1 | |
| SCHEMBL13157795 | 0.85 | POLB (0.55) | SLC18A3MGLLLMNAPOLBMEN1 | |
| SCHEMBL13158203 | 0.85 | POLB (0.55) | SLC18A3MGLLLMNAPOLBMEN1 | |
| SCHEMBL3088647 | 0.83 | MBTD1 (0.46) | SLC18A3MGLLLMNAMEN1KMT2A | |
| SCHEMBL13157694 | 0.83 | CHRM2 (0.47) | TSHRSLC18A3MGLLLMNAPOLB | |
| SCHEMBL3098517 | 0.83 | CHRM2 (0.47) | TSHRSLC18A3MGLLLMNAPOLB | |
| SCHEMBL13157824 | 0.83 | MBTD1 (0.46) | SLC18A3MGLLLMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399455-B2 | Compounds useful as chemokine receptor antagonists | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20100234356-A1 | COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234356-A1 | COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS | ACKR3, CCR5, CXCR2 | TSHR 696/4885RECQL 3092/4885SLC18A3 2263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.